Effect of empagliflozin vs. placebo on the primary endpoint (A), heart failure hospitalization (B), recurrent heart failure hospitalization (C), cardiovascular death (D), and all-cause death (E). Cox regression models were examined using prespecified covariates of age, sex, geographical region, diabetes status at baseline, left ventricular ejection fraction, eGFR at baseline, hypertension category and, hypertension category ∗ treatment interaction. CI, confidence intervals; CVD, cardiovascular death; HFH, heart failure hospitalization; HR, hazard ratio